Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
NRx Pharmaceuticals Q1 2026 Earnings Call - FDA Nears KETAFREE Approval, NRX-100 NDA Filing Imminent, MIND1 Trial Cleared
NRx Pharmaceuticals reported a 74% year-over-year reduction in net loss to $1.4 million, driven by strategic investments in drug development and clinic expansion. The company cleared its debt, secured...
- NRx Pharmaceuticals reduced its net loss by 74% year-over-year to $1.4 million ($0.04 per share) for Q1 2026, compared to $5.5 million in the prior year period.
- The company achieved debt-free status and raised $7 million in gross proceeds through its at-the-market equity facility subsequent to the quarter end.
- FDA issued a preliminary determination of bioequivalence for KETAFREE, preservative-free ketamine, with only minor formatting and administrative changes remaining.
- +9 more takeaways
Gossamer Bio Q1 2026 Earnings Call - FDA Pre-NDA Meeting Confirmed, Multi-Compartment Reverse Remodeling Data Strengthens Seralutinib Case
Gossamer Bio reported Q1 2026 results centered on its pulmonary arterial hypertension (PAH) candidate seralutinib. The company confirmed a Type B pre-NDA meeting with the FDA for mid-June 2026, aiming...
- Gossamer Bio confirmed a Type B pre-NDA meeting with the FDA for mid-June 2026, targeting an NDA submission in September 2026 and potential approval in Q3 2027.
- The PROSARA phase III trial showed a clinically meaningful 13.3-meter placebo-adjusted improvement in six-minute walk distance at week 24, meeting the traditional 0.05 significance threshold but missing the pre-specified 0.025 alpha.
- Management plans to submit the NDA based on one adequate and well-controlled study (PROSARA) plus confirmatory evidence (TORREY phase II), citing high unmet medical need and novel mechanism of action.
- +7 more takeaways
Niu Technologies Q1 2026 Earnings Call - Electric Motorcycle Surge Offsets E-Bike Transition and Overseas Inventory Clearing
Niu Technologies delivered a structurally transformative first quarter, with total sales jumping 28.7% year-over-year to 261,000 units and revenue surging 33.4% to RMB 909.52 million. The growth was e...
- Total sales volume reached 261,000 units, up 28.7% year-over-year, with revenue hitting RMB 909.52 million, up 33.4% year-over-year.
- Electric motorcycle sales in China surged threefold year-over-year, completely offsetting a temporary contraction in the electric bicycle market due to new national standards.
- Domestic sales rose 35.4% to nearly 248,000 units, driven by a strategic geographic shift from tier-1 cities to faster-growing tier-2 and tier-3 markets.
- +7 more takeaways
iQIYI Q1 2026 Earnings Call - AI-Driven Content Revolution and Overseas Surge
iQIYI's Q1 2026 results paint a picture of a company aggressively pivoting from a traditional studio model to an AI-powered content ecosystem, with overseas membership revenue surging 40% year-over-ye...
- Overseas membership revenue surged more than 40% year-over-year in Q1, driven by explosive growth in Southeast Asia, Latin America, and the Middle East, establishing international operations as a proven second growth engine.
- Management revealed the launch of Nado Pro, a proprietary AI production platform that has already onboarded over 10,000 active creators since its April commercial release, signaling a shift toward a decentralized content ecosystem.
- iQIYI launched over 3,000 AI-generated micro-dramas in Q1, with AI-native formats now comprising more than 14,000 titles in the library, drastically lowering production costs and expanding content supply.
- +9 more takeaways
Netlist Inc Q1 2026 Earnings Call - Record Revenue Driven by AI Memory Demand and IP Enforcement
Netlist delivered a record-breaking first quarter of 2026, with revenue surging 262% year-over-year to $104.9 million, fueled by a structurally undersupplied memory market and accelerating AI-driven d...
- Q1 2026 revenue reached $104.9 million, a 262% increase year-over-year, marking a record performance driven by tight memory supply and strong AI demand.
- Operating income improved by $18 million compared to Q1 2025, reaching $8.6 million, reflecting better gross margins and disciplined expense management.
- The operational cash cycle remained efficient at 16 days, with day sales outstanding improving by 3.5 days year-over-year.
- +7 more takeaways
HUYA Inc. Q1 2026 Earnings Call - Game Publishing and AI Pivot Drives Record Non-Streaming Revenue
HUYA Inc. is no longer just a live-streaming platform. It is actively repositioning itself as a full-service game ecosystem, and the Q1 2026 results prove the pivot is working. Game-related services, ...
- Game-related services, advertising, and other revenues surged 69% year-over-year to RMB 627 million, marking a record 36% share of total net revenue and signaling a successful structural shift away from pure live-streaming dependency.
- Goose Goose Duck Mobile has emerged as a breakout hit, ranking number one on the iOS free games chart for most of Q1 and climbing into the top five on the iOS top-grossing chart by April, validating HUYA's publishing capabilities.
- Total net revenues grew 15% year-over-year to RMB 1.73 billion, driven primarily by the explosive growth in game publishing, in-game item sales, and advertising, which offset a slight dip in traditional live-streaming revenue.
- +7 more takeaways
Petrobras Q1 2026 Earnings Call - Record Production and Refining Efficiency Drive Cash Flow Amid Geopolitical Tensions
Petrobras delivered a strong first quarter of 2026, producing 2.58 million barrels of oil per day and pushing April output to a record 2.73 million barrels per day. The company’s pre-salt assets, part...
- Q1 2026 production averaged 2.58 million barrels of oil per day, with April setting a new monthly record at 2.73 million barrels per day.
- New platforms P-78 and P-79 came online ahead of schedule in Búzios, each capable of producing 180,000 barrels per day.
- Refinery utilization reached 97.4% in Q1, the highest level since 2014, with S10 Diesel production hitting a record 512,000 barrels per day in March.
- +12 more takeaways
Arvinas Q1 2026 Earnings Call - First PROTAC Approved, VEPPANU Licensed to Rigel, Pipeline Advances Amid Cost Cuts
Arvinas delivered a landmark quarter with the FDA approval of VEPPANU, the first-ever PROTAC degrader, and a global licensing deal with Rigel Pharmaceuticals to commercialize the asset. The move allow...
- FDA approved VEPPANU (vepdegestrant), the first-ever PROTAC degrader, for ESR1 mutant, ER+ advanced breast cancer.
- Arvinas licensed global rights to VEPPANU to Rigel Pharmaceuticals, with Pfizer retaining a 50% interest in economics.
- Rigel will commercialize VEPPANU in the U.S. and manage international development, with Arvinas receiving upfront and milestone payments.
- +7 more takeaways
Abeona Therapeutics Q1 2026 Earnings Call - ZEVASKYN Revenue Surges as Company Bets on Novel Prostate Cancer Therapy
Abeona Therapeutics is moving from a rare disease orphan play to a broader cell therapy contender, and the market is watching the pivot closely. The company reported a sharp jump in ZEVASKYN revenue t...
- ZEVASKYN revenue surged 263% quarter-over-quarter to $8.7 million, driven by three commercial patients treated in Q1 2026 compared to just one in Q4 2025.
- The company has activated six Qualified Treatment Centers (QTCs), including NewYork-Presbyterian/Columbia and Children’s Hospital of Philadelphia, and is on track to add a seventh by year-end.
- A growing pipeline of over 100 identified patients across QTCs and community physicians suggests strong demand, with one patient biopsied and manufacturing underway, and six more expected this quarter.
- +9 more takeaways
Acurx Pharmaceuticals Q1 2026 Earnings Call - Ibezapolstat Clears Key Regulatory Hurdles with FDA's One-Trial Standard
Acurx Pharmaceuticals advanced its ibezapolstat program for recurrent C. difficile infection (rCDI) by launching an open-label pilot study targeting multiply recurrent patients, with plans for a phase...
- Acurx launched a 20-patient open-label pilot study for ibezapolstat in multiply recurrent C. difficile infection (rCDI), with first patient dosing expected around August 2026.
- The FDA recently issued final guidance that may allow single-trial approval for CDI, potentially ending the two-trial dogma and accelerating Acurx's path to market.
- Phase II data for ibezapolstat in acute CDI showed a 96% cure rate with zero recurrences in 25 patients, with five remaining recurrence-free at three months.
- +7 more takeaways